Skip to main content Skip to menu Skip to footer
Home
  • Who we are
  • Contact Us
  • Journalists
    • Patients and relatives
    • Donors
    • Researchers
    • Students
    • Caregivers
    • TechTransfer
Search
Directory of Doctors
  • FR
  • EN
Make a donation
  • Press Release
    • 2002-2022: DOSIsoft delivering 20 years of Innovation
    • Epigenetic treatments: New allies for chemotherapies?
    • Lung cancer: a new treatment combining immunotherapies and chemotherapy reduces risk of recurrence and death by almost 40%
    • Institut Curie’s key progress for the future of oncology
    • Biomunex and Institut Curie pursue strategic collaboration for development of disruptive non-conventional T cell redirection approach to treating cancer
    • Institut Curie equips its surgeons and radiologists with AVATAR MEDICAL’s virtual reality medical image solution
    • Retinoblastoma: an ambitious project to preserve children’s sight
    • Institut Curie celebrates the centenary of Marie Curie’s trip to the United States
    • Egle Therapeutics raises 40 million € Series Ato develop First-In-Class T-regulatory cells therapies based on Treg-starvers
    • PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors
    • New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies
    • Research / Breast cancers: ruptures in cell nuclei promotes tumor invasion
    • Research / FROM YELLOW TO WHITE AND BACK AGAIN: THE SECRET TO THE SPIDER CRAB’S COLOR CHANGES
    • Prof. Steven Le Gouill, new Director of the Hospital Group at Institut Curie
    • Accelerating the pace of pediatric oncology research and innovating at Institut Curie, to better care for young patients
    • Institut Curie applauds the €75 million fundraising achieved by its spin-off Mnemo Therapeutics
    • Nanomedicine and new targeted therapies: the advances of Institut Curie at the ASCO 2021 Meeting
    • LEBANON: Institut Curie steps up its support in oncology
    • “Flash" radiotherapy: another step towards clinical applications for Institut Curie and SIT
    • OncoDNA and Institut Curie test the clinical utility of personalized liquid biopsy in head and neck cancers
    • PEP-Therapy and Institut Curie granted approval from ANSM to start first-in-human clinical trial of PEP-010 for the treatment of advanced solid tumors
    • Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children
    • Autoimmune and inflammatory diseases associated with primary immune deficiencies
    • Keeping Sperm Cells on Track
    • Covid-19: biological bait in the form of vesicles to stop infection by the SARS-CoV-2 virus
    • COVID-19: early results of a large-scale study on the immune response against SARS-CoV-2 conducted with the help of Institut Curie staff
    • Institut Curie and Google initiate a research collaboration using artificial intelligence (AI) for the analysis of complex transcriptomic and epigenetics data
    • Intestinal Health : Macrophages lead the conversation between the microbiota and the colon
    • Cell multiplication : measuring up
    • Iron-mediated cancer cell activity: a new regulation mechanism
    • APPOINTMENT: Alain Puisieux, new director of Institut Curie Research Center
    • Institut Curie names Intel lead partner...
    • Institut Curie and Pierre Fabre initiate a novel partnership in immuno-oncology
    • Servier and Institut Curie extend duration and scope of partnership
  • Understanding cancer
Breadcrumb
  1. Institut Curie
  2. Journalists
  3. News
Find out about our latest news.
Traitement épigénétique
Publication
Epigenetic treatments: New allies for chemotherapies?05/04/2022
Projet Cutok-Gut Pedro Hernandez
Publication
Understanding the communication between the microbiota, immunity and intestinal cells 05/04/2022
Laboratoire
Innovation
A confirmed success for Institut Curie's patented inventions04/26/2022
Nicolas Girard
AACR
Lung cancer: a new treatment reduces the risk of recurrence and death by almost 4004/11/2022
AACR 2022
AACR
Institut Curie at AACR Annual Meeting 202204/09/2022
cancer sous pression
Publication
Cancer under pressure 03/31/2022
Immunofluorescence sur une tumeur mammaire
Publication
Macrophage populations in breast cancer03/30/2022
COMPRENDRE L’ARCHITECTURE ET L’ORGANISATION DES CENTROMÈRES
Publication
UNDERSTAND THE ARCHITECTURE AND ORGANIZATION OF CENTROMERES03/22/2022
Tanzanie
Openness
Institut Curie in Tanzania, jointly heads an ambitious and engaged program to fight cancer12/14/2021
épigénétique
Publication
How do our cells pass on their epigenetic markers?11/19/2021

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Page suivante Next Page
  • Last page Last Page
Sign up to our Newsletter
Join us
Follow us
  • facebook
  • twitter
  • linkedin
  • instagram
Patients and relatives
  • Our hospitals
  • Adult care
  • International patients
  • What is a clinical trial?
  • Care News
Access this area
Donors
  • Who we are
  • Understand cancer
  • Support us
  • Strategic priorities
  • Annual report
  • Research News
Access this area
Researchers
  • Research Center
  • Thematic areas of research
  • Research Units
  • Research Teams
  • Core Facilities
  • Seminars
  • Programs and partnerships
  • Training
  • Join us
  • Research News
Access this area
Students
  • Courses
  • The hospital
  • The Research Center
  • Collaborations
  • ADIC
  • Training News
Access this area
Caregivers
  • Refer a patient
  • Understanding cancer
  • Our expertise
  • Our hospitals
  • Contact Us
  • Care News
Access this area
Journalists
  • Press Release
  • Understanding cancer
Access this area
TechTransfer
  • About us
Access this area
  • Copyright © 2022
  • Contact and Access
  • Contact Us
  • Directory
  • Join us
  • Legal Notice
  • Personal data protection charter